Shahram Hejazi

Founder of Optimeos Life Sciences

Princeton, New Jersey

Overview

Shahram Hejazi is a Venture Capital Investor and Managing Director & CEO at BioAdvance, with a background spanning leadership roles at renowned companies like Kodak and Siemens Medical Solutions. He has successfully invested in a diverse range of startups in the lifesciences sector, including companies like Halo Labs and Cohero Health, demonstrating expertise in R&D, commercialization, and technology transfer. As of October 2021, Shahram Hejazi is leading BioAdvance as its Managing Director & CEO, while also serving as a Faculty member at Princeton University. His career highlights include founding Optimeos Life Sciences and holding executive positions at Zargis Medical Corporation and Kodak's Carestream Health division.

Work Experience

BioAdvance Capital

Managing Director & CEO
2008 - Current
BioAdvance is a 22-year-old venture capital firm specializing in early-stage investments across biotech, digital health, diagnostics, and medical devices, with a portfolio of over 120 companies since inception. Joined the firm as a Partner and was appointed Managing Director & CEO in October 2021. In this role, responsible for overall leadership and strategic direction, as well as leading select investments. Currently serve on the Board of Directors for several portfolio companies, including BainBridge, Keriton, Halo Labs, Talex Medical, and Wellsheet.

Princeton University

Faculty and Head of Entrepreneurship
2014
Began as the 2014 James Wei Professor of Entrepreneurship and currently a Faculty and Head of the Entrepreneurship Program, teaching two high-level courses in Entrepreneurship and Venture Capital/Finance of Innovation. The courses which often receive Dean's recognition for Teaching Excellence, are also part of Minor Programs in Entrepreneurship, Finance, and Technology & Society. Lead the development of the Entrepreneurship Curriculum and the Entrepreneurship Program.

Optimeos Life Sciences

Founder and CEO
2019
A venture-backed non-viral in vivo gene therapy company based on a transformative polymeric (non-lipid based) platform exclusively licensed from Princeton University.

Optimeos Life Sciences is a biotechnology company that enables the use of biologics, peptides, and RNA to treat diseases.

Raised $631,000.00 from NJEDA, National Science Foundation and National Science Foundation.

optimeos.com